111 Capital Acquires New Position in Bristol-Myers Squibb (NYSE:BMY)

111 Capital acquired a new position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 17,532 shares of the biopharmaceutical company's stock, valued at approximately $992,000.

Other large investors also recently modified their holdings of the company. Pinney & Scofield Inc. acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $25,000. Park Square Financial Group LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $26,000. Transce3nd LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $28,000. Fairway Wealth LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $28,000. Finally, Comprehensive Financial Planning Inc. PA acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $34,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BMY. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Jefferies Financial Group dropped their target price on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Finally, Piper Sandler began coverage on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $58.00.

Bristol-Myers Squibb Stock Performance

Bristol-Myers Squibb stock traded up $0.41 during trading hours on Friday, hitting $48.26. The company had a trading volume of 20,756,575 shares, compared to its average volume of 13,135,047. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33. The firm has a 50-day moving average of $50.71 and a 200 day moving average of $55.46. The firm has a market cap of $98.21 billion, a PE ratio of -10.92, a PEG ratio of 2.07 and a beta of 0.39. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. During the same period last year, the firm earned ($4.40) earnings per share. The business's revenue for the quarter was down 5.6% on a year-over-year basis. On average, sell-side analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were issued a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.14%. Bristol-Myers Squibb's dividend payout ratio is presently 92.88%.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of the stock in a transaction dated Friday, April 25th. The shares were bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the acquisition, the executive vice president now owns 83,513 shares of the company's stock, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.